On May 27, FDA expanded the indication for rimegepant (Nurtec ODT—Biohaven) to include preventive treatment in adults with episodic migraine, defined as fewer than 15 headache days per month.
Cara Aldridge Young
In today’s climate of self-management for optimal health and wellness, use of prebiotics and probiotics has become increasingly popular.
Daniel L. Krinsky, RPh, MS
Many patients with chronic pain turn to alternative, complementary therapy as part of their pain management. Acupuncture has been gaining legitimacy for decades and was approved as a medical therapy in the United States in the 1990s.
Mickie Cathers
Updates from FDA
FDA has approved Azstarys (KemPharm), the first ADHD medication to combine two medications, 70% serdexmethylphenidate (SDX) and 30% immediate-release dexmethylphenidate (d-MPH), in a oncedaily capsule for treatment of ADHD in patients ages 6 years and older.